The Immune Cell With Two Faces
When your liver is under attack — from a virus, excess fat, or years of inflammation — your body sends in immune cells to manage the damage. One of the most important of these is called a macrophage (mak-roh-fayj), a type of cell that can engulf harmful particles, signal other immune cells, and help coordinate repair.
For a long time, scientists thought macrophages were either "good" (promoting healing) or "bad" (causing damage). That simple picture, it turns out, is wrong.
Liver Disease Affects More People Than You Think
Liver diseases are among the most common serious conditions worldwide. Fatty liver disease — known formally as metabolic dysfunction-associated steatotic liver disease, or MASLD — affects roughly one in three adults in many countries. Hepatitis B infects around 296 million people globally. And liver fibrosis, where scar tissue builds up over time, can silently progress to cirrhosis (severe scarring) or liver failure without any obvious symptoms for years.
Despite how widespread these conditions are, treatments remain limited. Most current approaches either broadly suppress the immune system or target single molecules, with limited success in stopping long-term damage.
The Old Thinking Doesn't Hold Up
Scientists used to sort macrophages into two camps: M1 (the "fighters" that cause inflammation) and M2 (the "peacemakers" that promote healing). Treatment strategies were built around this idea — suppress M1 activity, boost M2 activity.
But here's the twist: new research shows that liver macrophages don't stay in one camp. Different subtypes exist, and some of them do both jobs at the same time.
What Makes Liver Macrophages So Complicated
Think of your liver's macrophages like a construction crew that has been hired both to tear down a condemned building and to build a new one. If the timing is off — if demolition continues while new walls are going up — you end up with chaos rather than a repaired structure.
In the liver, certain macrophage subtypes marked with proteins like CCR2 tend to show up early in injury and drive inflammation. Later, a different wave marked with MerTK helps clean up debris and push healing forward. In chronic disease, two more subtypes labeled CD9+TREM2+ and CD300E+ can be present at the same time — one pushing disease forward, the other trying to hold it back. The balance between these subtypes may determine whether a patient's liver heals or continues to deteriorate.
This article is a comprehensive scientific review — rather than a single trial — that synthesizes findings from many recent studies on liver macrophage biology. It covers evidence from patients with hepatitis B infection, fatty liver disease, and liver fibrosis, as well as emerging experimental therapies targeting specific macrophage subtypes.
The review finds that macrophages are far more diverse and adaptable than earlier models suggested. Rather than acting as simple switches set to "attack" or "repair," they shift roles depending on what signals they receive and how far disease has progressed.
Critically, some subtypes that were previously thought to be purely harmful appear to have protective functions under certain conditions — and vice versa. This means that broadly suppressing all macrophage activity could accidentally shut down the body's own repair mechanisms.
Treatments targeting liver macrophages are still mostly in early research phases and are not yet widely available.
Here's Where Things Get Interesting
Some of the most promising early work involves engineered immune cells — called CAR-M cells — that are designed to seek out and neutralize only the harmful macrophage subtypes while leaving the repair-promoting ones alone. This approach is similar in concept to CAR-T cell therapy used in some cancers, adapted for a different cell type.
Fitting Into the Bigger Picture
This review reflects a broader shift in medicine away from one-size-fits-all treatments and toward therapies tailored to a patient's specific biological profile. For liver disease, that means moving beyond simple inflammation-suppression and toward interventions that work with the liver's own healing machinery rather than against it.
If you have been diagnosed with fatty liver disease, hepatitis B, or liver fibrosis, it is worth asking your doctor about the current state of immune-based treatments for your condition. While most precision macrophage therapies are not yet available outside clinical trials, new options are being developed. Monitoring your condition closely and keeping follow-up appointments remains the most important step you can take right now.
This is a review article, not a clinical trial, so it does not test a specific treatment or measure outcomes in patients directly. Much of the underlying research was conducted in mice, and results from animal studies do not always translate to humans. The precise role of each macrophage subtype in human disease is still being worked out.
Researchers are now using advanced tools — including spatial multi-omics (techniques that map gene activity across different regions of a tissue) and high-resolution imaging — to understand exactly where and when each macrophage subtype does its work inside the liver. The goal is to develop therapies precise enough to turn off the harmful subtypes and amplify the helpful ones, without disrupting the balance the liver needs to heal itself.
